2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of testThe effect of incarceration on TB treatment outcomes
O Marr J, Gonçalves C, Arakaki-Sanchez D, Pelissari D, Costa F, Croda J, Walter K, Andrews J. The effect of incarceration on TB treatment outcomes. The International Journal Of Tuberculosis And Lung Disease 2022, 26: 252-258. PMID: 35197165, DOI: 10.5588/ijtld.21.0449.Peer-Reviewed Original ResearchMeSH KeywordsDirectly Observed TherapyHumansOdds RatioPrisonersPrisonsRisk FactorsTreatment OutcomeTuberculosisConceptsNon-incarcerated individualsTreatment successTreatment outcomesDrug-susceptible TB casesImproved treatment successTB treatment outcomesTB treatment successClinical risk factorsIncarcerated individualsMultivariate logistic regressionGreater treatment successTB casesClinical factorsObserved therapyPoor outcomeTB notificationsRisk factorsElevated riskGreater efficacyLogistic regressionNotifiable diseaseOutcomesIncarcerated populationsVulnerable individualsUse of DOT
2015
A Cross-Sectional Survey of HIV Testing and Prevalence in Twelve Brazilian Correctional Facilities
Sgarbi RV, da Silva Santos Carbone A, Paião DS, Lemos EF, Simionatto S, Puga MA, Motta-Castro AR, Pompilio MA, Urrego J, Ko AI, Andrews JR, Croda J. A Cross-Sectional Survey of HIV Testing and Prevalence in Twelve Brazilian Correctional Facilities. PLOS ONE 2015, 10: e0139487. PMID: 26466312, PMCID: PMC4605759, DOI: 10.1371/journal.pone.0139487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnti-Retroviral AgentsBrazilCross-Sectional StudiesFemaleHealth Services AccessibilityHIV InfectionsHumansMaleMass ScreeningMiddle AgedMultivariate AnalysisOdds RatioPrevalencePrisonersPrisonsSurveys and QuestionnairesSyphilisVulnerable PopulationsYoung AdultConceptsHIV testingHIV careMental illnessMultivariable logistic regression modelPrevious HIV testingHIV testing ratesMajority of HIVHIV testing practicesTreatment of HIVHigh HIV prevalencePopulation-based samplePercent of participantsLogistic regression modelsAntiretroviral therapyHIV diagnosisPrevious surgeryHIV infectionHIV statusMultivariable analysisHIV prevalenceSyphilis testingClinical careGeneral populationHIVTesting rates
2009
Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit
Croda J, Croda M, Neves A, dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Critical Care Medicine 2009, 37: 1605-1611. PMID: 19325488, PMCID: PMC4143892, DOI: 10.1097/ccm.0b013e31819da8c7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveBrazilCohort StudiesConfidence IntervalsCritical CareCritical IllnessDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHospital MortalityHumansIntensive Care UnitsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisConceptsIntensive care unitAntiretroviral therapyICU admissionCare unitChronic Health Evaluation II scoreHuman immunodeficiency virus-infected patientsCD4 T-cell countUse of ARTTertiary care teaching hospitalMultivariate logistic regression analysisCox proportional hazards modelAcute illness severityRetrospective cohort studyT-cell countsVirus-infected patientsDay of admissionHuman immunodeficiency virusCause of admissionProportional hazards modelPotential confounding factorsLogistic regression analysisAcute PhysiologyICU mortalityII scoreCohort study